No patients were taking steroids or benzodiazepines, and there was no significant difference between the 2 VS groups in the proportion of patients with either nonaudiological symptoms (P > .05) or associated medical comorbidities thought to affect brain TSPO expressions such as hypertension, type II diabetes and depression (P > .05, Fisher’s exact test). This evidence concerns the gene TSPO and major depressive disorder.